macrolides

Potential for Use of Spiramycin in Clinical Practice

Spiramycin, natural 16-membered macrolide antibiotic, was discovered in 1954. This antimicrobial agent is at least non-inferior to and has some advantages over the currently available macrolides in spectrum of activity, pharmacological properties, …

Asthma associated with Chlamydophila pneumoniae-infection

The present open-label, randomized, comparative study of efficacy of 8-week Azithromycin therapy in mildto-moderate stable asthma included 71 patients. After evaluation for C. pneumoniae infection by serologic tests, patients where randomized into 4 …

Efficacy and Safety of Josamycin in the Treatment of Mild-to-Moderate Community-Acquired Pneumonia: Results of Multicenter Clinical Study

Multicenter prospective non-comparative open-label clinical study to assess clinical and microbiological efficacy and safety of josamycin (16-memebered macrolide) in adults with non-severe community-acquired pneumonia (CAP) was performed. Patients …

Clarithromycin: is There Potential for Clinical Use in the 21th Century?

Clarithromycin – 14-membered macrolide antibiotic that has been used in clinical practice since 1991. This review presents up-to-date data on pharmacokinetics, pharmacodynamics, drug interactions, safety profile of clarithromycin, including its novel …

Spiramycin: the classic and the present

Spiramycin is classic representative of the 16-membered macrolides, which was synthesized in 1954. Nevertheless he keeps his clinical significance due to the high activity against typical causative agents of respiratory tract, skin and soft tissues …

The Role of Newer Macrolides in the Treatment of Community-Acquired Respiratory Tract Infections: a Review of Experimental and Clinical Data

The macrolide class of antibiotics is well established and often recommended for use in the treatment of community-acquired respiratory tract infections (RTI). The newer agents clarithromycin and azithromycin are frequently prescribed as firstor …